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Abstract
Background: Hypertensive disease in pregnancy remains the leading cause of maternal mortality in the
Netherlands. Seventeen percent of the clinical pregnancies are complicated by hypertension and 2% by
preeclampsia. The Dutch Society of Obstetrics and Gynaecology (NVOG) has developed evidence-based guidelines
on the management of hypertension in pregnancy and chronic hypertension. Previous studies showed a low
adherence rate to other NVOG guidelines and a large variation in usual care in the different hospitals. An
explanation is that the NVOG has no general strategy of practical implementation and evaluation of its guidelines.
The development of an effective and cost effective implementation strategy to improve adherence to the
guidelines on hypertension in pregnancy is needed.
Methods/Design: The objective of this study is to assess the cost effectiveness of an innovative implementation
strategy of the NVOG guidelines on hypertension including a computerised decision support system (BOS)
compared to a common strategy of professional audit and feedback. A cluster randomised controlled trial with an
economic evaluation alongside will be performed. Both pregnant women who develop severe hypertension or
pre-eclampsia and professionals involved in the care for these women will participate. The main outcome
measures are a combined rate of major maternal complications and process indicators extracted from the
guidelines. A total of 472 patients will be included in both groups. For analysis, descriptive as well as regression
techniques will be used. A cost effectiveness and cost utility analysis will be performed according to the intention-
to-treat principle and from a societal perspective. Cost effectiveness ratios will be calculated using bootstrapping
techniques.
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Hypertension is a common complication of pregnancy.
Seventeen percent of the clinical pregnancies are com-
plicated by hypertension and 2% by preeclampsia [1-6].
Severe hypertension and preeclampsia (hypertension and
proteinuria) pose an increased risk for morbidity and
mortality to both the mother and the foetus. Major
maternal complications (e.g., eclampsia, HELLP syn-
drome, pulmonary oedema, placental abruption, liver
haematoma, severe infectious or thrombotic morbidity,
encephalopathy) were recently reported in 74 of 216
(34%) Dutch pregnant women with severe hypertension
or preeclampsia [7,8]. The Dutch trends in maternal
morbidity due to severe hypertension and preeclampsia
are currently a reason for great concern [9]. Hyperten-
sive disease in pregnancy remains the leading cause of
maternal mortality in the Netherlands, followed by
thromboembolism and obstetric haemorrhage. Fifty-one
percent of the total number of maternal deaths is a
result of hypertensive complications in pregnancy. The
maternal mortality ratio (MMR; deaths per 100,000 live
births) from hypertensive disease in pregnancy increased
from 2.7 in 1983 to 1992 to 4.0 in 1993 to 2002 [10], a
major difference with surrounding countries. In the UK,
maternal mortality due to hypertensive disease ranks
fourth place– with a MMR of 0.7 – following throm-
boembolism, obstetric haemorrhage, and death during
first trimester (ectopic pregnancies, miscarriage, and ter-
mination of pregnancy) [11].
It is thought that a high degree of these maternal
complications results from suboptimal or insufficient
treatment [12,13]. A recent study of the Dutch Commit-
tee on Maternal Death showed that in 96% of the cases
of maternal death due to hypertensive disease several
factors of substandard care were present. For instance,
in 85% of this patient group, treatment of severe hyper-
tension was inadequate. In many cases, the decision to
start therapy was either made too late or not at all [14].
Therefore, management of hypertension is an important
part of care for pregnant women for which improve-
ment is necessary. To support their members, the Dutch
Society of Obstetrics and Gynaecology (NVOG) has
developed evidence-based clinical guidelines on the
management of hypertension in pregnancy [15] and
chronic hypertension in pregnancy [16]. However, these
guidelines are not yet implemented. The NVOG has no
general strategy of practical implementation and evalua-
tion of its guidelines, and has only just begun with a
policy of hospital visitations in order to improve quality
of clinical care. In order to reduce maternal complica-
tions, an implementation strategy to improve adherence
t ot h eg u i d e l i n e so nh y p e r t e n s i o ni np r e g n a n c yi s
necessary
Original studies and systematic reviews about the
effectiveness of different interventions to change clinical
practice show that a widely used strategy for implement-
ing guidelines consists of audit and feedback about
actual performance. This strategy has shown to be effec-
tive, but feedback is often recommended in combination
with other strategies [17]. In a recent systematic review,
a major benefit of implementing health information
technology on increased adherence to guideline-based
care was demonstrated, including hypertension [18]. Dif-
ferent health information technology systems were
reviewed. Most of them included a decision support sys-
tem, and some of them integrated clinical guidelines
[19]. In case of hypertension in pregnancy, an imple-
mentation strategy including a computerised decision
support system (BOS) may lead to a higher compliance
to the guidelines’ recommendations and thus a lower
rate of maternal complications and their costs. This will
be tested in this study.
It is expected that an increased adherence to the
guidelines’ recommendations will reduce the number of
major maternal complications. By reducing the number
of major maternal complications, we expect a reduction
in health care costs (e.g., costs of hospitalisation, medi-
cation), costs in other sectors, patient and family costs,
and costs of production losses [20]. Estimating the size
of this cost reduction is an essential part of this study.
Objectives
The objective of this study is to assess the effectiveness
and cost effectiveness of an innovative implementation
strategy of the NVOG guidelines on hypertension, includ-
ing a computerised decision support system compared to
a common strategy of professional audit and feedback.
The research questions are:
1. To what extent is an innovative strategy using a
computerised decision support system cost effective
compared to a common strategy of professional audit
and feedback in implementing the NVOG guidelines on
hypertension in pregnancy?
2. What is the feasibility of the two implementation
strategies?
3. What is the cost effectiveness of the two strategies
to implement the guidelines on hypertension in preg-
nancy in clinical practice?
Methods/Design
Study design
A cluster randomised controlled trial with an economic
evaluation alongside will be performed. The chosen
implementation strategies are:
1. A common strategy consisting of professional audit
and feedback.
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the barriers and facilitator st h a ta r ef o u n di nap i l o t
study and professional audit and feedback.
Preparation
The first part of the study consists of the development
of a set of quality indicators extracted from the NVOG
guidelines on hypertension in pregnancy. The indicator
development will be performed according to the RAND-
modified Delphi method [21]. First, key recommenda-
tions from the guidelines will be extracted by two or
three experts (project leaders). Subsequently, the rele-
vance of all key recommendations for patient’sh e a l t h
benefit (clinical relevance) and efficacy will be tested in
two rounds among an independent panel of 12 to 15
experts. The opinion leaders of clinical obstetrics, in
particular regarding hyperten s i o ni np r e g n a n c y ,a sw e l l
as members of the NVOG committees on maternal
death, guidelines, implementation and quality, quality of
care experts, and patients’ organisation Stichting HELLP
are involved in this expert panel. The key recommenda-
tions with the highest scores will be selected and opera-
tionalised in measurable elements (process indicators).
Based on this set of quality indicators, the BOS for the
guidelines on hypertension in pregnancy will be further
developed. Moreover, measurement instruments will be
developed and the participating hospitals will be
informed about the study.




The innovative strategy will be tested in one of the par-
ticipating hospitals to explore its feasibility.
Implementation study
An effect and process evaluation will be performed. An
effect evaluation of the two strategies will be carried out
using the primary and secondary outcome measures.
This will be done among pregnant women who develop
severe hypertension or preeclampsia and professionals
involved in the care for these women. The measure-
ments will be performed in 20 participating hospitals
before and after implementation of the different strate-
gies by a medical record search, added with question-
naires among professionals and patients. The medical
record search will be done using standardised registra-
tion forms. Follow-up of the patients will be six months
after delivery.
A process evaluation will be performed to study the
feasibility of the two strategies. The extent by which clini-
cians, nurses, and patients used BOS and the other ele-
ments of the strategies (audit and feedback) and their
experiences with these elements will be measured. The
process information regarding to what extent profes-
sionals used BOS will be collected by the application
itself. The system will register relevant data of participat-
ing professionals and their patients. This will allow us to
analyse the relation between the use of BOS and the pri-
mary and secondary outcome measures. To measure the
experiences with BOS and the other elements of the two
strategies, personal interviews will be held among 10 to
15 gynaecologists, nurses, and patients. This will provide
insights into possible barriers and facilitators for and
satisfaction with using BOS. T h ep o s s i b l eb a r r i e r sa n d
facilitators will be quantified with questionnaires among
all participating professionals and patients.
For analysis, descriptive as well as regression techni-
ques will be used. A cost effectiveness and cost utility
analyses will be performed according to the intention-
to-treat principle and from a societal perspective. Cost
effectiveness ratios will be calculated using bootstrap-
ping techniques (see economic evaluation).
Participants
Gynaecologists of 20 Dutch hospitals (university-based,
teaching and non teaching) will be invited for participa-
tion. Pregnant women who develop severe hypertension
or preeclampsia (in accordance to guidelines definitions)
in these hospitals will be included. It appears from
Dutch data that immigrants are at increased risk for
preeclampsia [22]. This is the reason why patient char-
acteristics like age, race, and cultural background will be
included in a multilevel analysis. Exclusion criteria are
refusal to participate or a diagnosis of lethal fetal conge-
nital abnormalities.
This study will be conducted within the framework of
the Otterlo group (a NVOG working group that devel-
ops obstetrical guidelines). Representatives of eight aca-
demic hospitals and two large teaching hospitals
participate in this group. Representatives of another 10
related hospitals will be invited to participate. These
hospitals are currently collaborating in the Dutch Peri-
natal Research Consortium http://www.studies-obsgyn.
nl/index.asp.
Interventions
Innovative strategy including a computerised decision
support system. We performed a pilot-study to make an
inventory of the barriers and facilitators for adherence
to the guidelines on hypertension in pregnancy. Barriers
can arise at different stages in the healthcare system at
the level of the individual professional (i.e., lack of
knowledge or skills, resistance against working with pro-
tocols); of the healthcare team (i.e., lack of knowledge or
skills, insufficient collaboration); of the patient (i.e.,
unwillingness, difficult guideline adherence for some
patient groupes); of the healthcare organisation (i.e., lack
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adequate care); and of the wider environment (i.e., lack
of financial incentives, misuse of guideline in medical
disciplinary law) [20]. Barriers can also arise at the level
of the innovation (guideline) itself (i.e., doubting evi-
dence of the guideline, poor layout, unclear decision
tree, unclear content). In a pre-study among 14 gynae-
cologists in 11 different hospitals (university medical
centres, teaching and non-teaching hospitals), we deter-
mined which barriers at which level were present
regarding the implementation of the guidelines on
hypertension in pregnancy. The main barriers proved to
be at the level of the guideline itself. A poor layout to
use the guideline showed the highest score (64%). Doubt
about a clear decision tree behind the guideline scored
also high (57%). Furthermore, 36% of the gynaecologists
mentioned that ‘the guideline could easy be misused in
medical disciplinary law,’‘ the content of the guideline
was unclear,’ and that ‘there was not enough room to
consider patients wishes.’ Moreover, 50% of the gynae-
cologists doubted about the accuracy of certain parts of
the guideline. The implementation strategy will be based
on these barriers and facilitators. We will use a compu-
terised decision support system, which is a commercial
web application developed by Giant-Soft in Leeuwarden,
the Netherlands. A similar system has been tested and
evaluated using another clinical guideline. The system
appeared feasible in clinical practice: most users (95%;
34 of 36) were satisfied with its use and 78% (28 of 36)
would prefer to maintain and extend the application to
other guidelines [23,24]. In our opinion, BOS can be a
solution for the main barriers regarding layout of, and
decision tree behind, the guideline. In this way, BOS is
tailored to the barriers ‘possible misuse in the medical
disciplinary law’ and ‘not enough room to consider
patients’ wishes.’ In this strategy, we will combine BOS
with professional audit and feedback (see control
intervention).
Control intervention
The control intervention will consist of professional
audit and feedback only. We will perform a retrospec-
tive medical record search (audit) for patients with pree-
clampsia in the 20 hospitals, university hospitals,
teaching and non-teaching hospitals. These records will
be checked for the extent of adherence to the quality
indicators developed from the guideline Hypertensive
Disorders In Pregnancy. Feedback about the results of
the audits will be given in a face-to-face meeting.
Outcome measures
Primary outcome
The primary outcome measure for the evaluation of the
effectiveness of both strategies is a combined rate of
major maternal complications (maternal death, organ
specific complications of hypertension, HELLP syn-
drome, placental abruption).
Secondary outcomes
Secondary outcome measures for effectiveness are
guidelines’ adherence rates, fetal death rates, Caesarean
delivery rates, and rates of neonatal mortality and mor-
bidity. To measure guidelines’ adherence rates, process
indicators will be established after selection of key
recommendations with the highest scores in the RAND-
modified Delphi method.
In the process evaluation, experiences with the imple-
mentation strategies are measured. This includes both
parameters regarding the participation and presence of
the professionals at the feedback meeting and patients
in the implementation activities; in particular, the use of
the BOS application at patient level as parameters
regarding their satisfaction with BOS and the other
implementation activities and their meaning about the
feasibility (barriers and facilitators) of these activities.
Sample size
The rate of major maternal complications in 216 Dutch
patients with severe hypertension or preeclampsia was
reported as 34% [7,8]. In 96% of cases of maternal
death, care was suboptimal with insufficient treatment
of hypertension in about half of these [14]. It is expected
that an increased adherence to the guidelines’ recom-
mendations will reduce the number of major maternal
complications by one-half, i.e., from 34% to 17%. Con-
sidering an intracluster correlation of 0.05, 20 hospitals
will have to be included with approximately 20 patients
each in order to get a reliable estimate (alpha = 0.05;
power = 0.80) of a 50%-difference (34 verus 17%) in
major maternal complications between both groups. If it
is assumed that 15% of participants will drop out or be
lost to follow up, 472 eligible women will have to be
included. It also is assumed that the total number of
deliveries in the participating hospitals is 30,000 (during
18 months of inclusion in 20 hospitals) and the inci-
dence of severe hypertension and preeclampsia is 2%. It
is estimated that the source
population consists of 600 eligible women. Thus, the
expected number of inclusions per month will be 33 in
20 hospitals, i.e., one or two per hospital. The minimum
required number of inclusions for randomisation per
month is 26 [see figure 1 for flowchart].
Data analysis
To analyse the effectiveness of the two implementation
strategies with regard to the primary and secondary out-
comes and process indicators, descriptive as well as
regression techniques will be used. The analysis will
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two intervention groups, as well as a multi-level analysis.
The latter will incorporate the levels of gynaecologist,
patient, and time measurements. The process informa-
tion regarding to what extent professionals used BOS
will allow us to analyse the relation between the use of
BOS and the primary and secondary outcome measures.
Process information will also give us insight into the
experiences of the participants (both satisfaction and
feasibility) with the BOS and the other implementation
activities.
Economic evaluation
The economic evaluation (cost effectiveness and cost
utility analysis) will be performed according to the
intention-to-treat principle and from a societal perspec-
tive. Healthcare costs (costs of hospitalisation, medica-
tion), costs in other sectors, patient and family costs,
and costs of production losses are included. Quality
adjusted life years (QALYs) are used as the main health
outcome measure for the cost-utility analysis. Incremen-
tal cost effectiveness ratios (ICER) will be estimated
using bootstrapping techniques and graphically pre-
sented on cost effectiveness planes. Sensitivity analysis
on the most important assumptions will be performed
in order to assess the robustness of the results.
QALYs will be calculated as the area under the health
utility profile, with straight-line interpolation between
utilities at each follow up. Utilities will be obtained
using the EuroQol (EQ-5D) instrument. Health states
will be estimated using reference values from a repre-
sentative Dutch sample. ICER will be estimated using
bootstrapping techniques and graphically presented on
cost effectiveness planes. Sensitivity analysis on the most
important assumptions will be performed in order to
assess the robustness of the results.
The input of the implementation strategies will be
assessed by collecting volumes of consumed resources
and multiplying these by the price of each resource unit
(market or guideline price). The output of the imple-
mentation strategies will be determined by the guide-
lines adoption rate, measured at fixed intervals during
the study and the speed of adoption. Welfare losses will
be determined by empirically established diffusion
curves (one diffusion curve per strategy) and quantified
by calculating the welfare change (monetarized variation
in indicators/benchmarks compared to guideline) at the
different time intervals adjusted for the complement of
the adoption rate at a particular time interval. The deci-
sion criterion on which the efficient implementation
strategy will be selected is the minimum welfare loss
compared to the guideline programme over time
Figure 1 flowchart randomisation and inclusion.
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tainty on the decision criterion will be evaluated by sen-
sitivity analyses.
Discussion
This study addresses an important problem, because
hypertensive disease in pregnancy is the main cause of
maternal mortality in the Netherlands and analysis of
these deaths suggests 96% received substandard care.
This indicates that there is room for improvement of
the management of care for this group of pregnant
women [14].
Clinical guidelines aim to promote evidence-based
practice, improve patient outcome, and allow more effi-
cient use of resources [25]. In a previous study of the
NVOG guideline on intra-uterine insemination, yet to
be publicised, it was demonstrated that there was a
favourable cost effectiveness ratio regarding adherence
to the main indicators of that guideline. Similar results
are assumed for the NVOG guidelines on hypertension
in pregnancy and chronic hypertension.
This study will also allow us to ascertain which ele-
ments of a multifaceted strategy can be particularly
associated with successful implementation of the guide-
lines on hypertension in pregnancy in the hospital set-
ting. The results of our study can contribute to more
knowledge about the effectiveness of a health informa-
tion technology intervention on guideline
implementation.
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